Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria

Christine Vande Velde*, Timothy M. Miller*, Neil R. Cashman§, and Don W. Cleveland*¶

*Ludwig Institute and Departments of Medicine and Neuroscience, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0670; and §Department of Medicine (Neurology) and Brain Research Centre, University of British Columbia Hospital, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5

Contributed by Don W. Cleveland, December 27, 2007 (sent for review December 10, 2007)

Mutations in copper/zinc superoxide dismutase (SOD1) are causative for dominantly inherited amyotrophic lateral sclerosis (ALS). Despite high variability in biochemical properties among the disease-causing mutants, a proportion of both dismutase-active and -inactive mutants are stably bound to spinal cord mitochondria. This mitochondrial proportion floats with mitochondria rather than sedimenting to the much higher density of protein, thus eliminating coincidental cosedimentation of protein aggregates with mitochondria. Half of dismutase-active and ~90% of dismutase-inactive mutant SOD1 is bound to mitochondrial membranes in an alkali- and salt-resistant manner. Sensitivity to proteolysis and immunoprecipitation with an antibody specific for misfolded SOD1 demonstrate that in all mutant SOD1 models, misfolded SOD1 is deposited onto the cytoplasmic face of the outer mitochondrial membrane, increasing antigenic accessibility of the normally structured electrostatic loop. Misfolded mutant SOD1 binding is both restricted to spinal cord and selective for mitochondrial membranes, implicating exposure to mitochondria of a misfolded mutant SOD1 conformer mediated by a unique, tissue-selective composition of cytoplasmic chaperones, components unique to the cytoplasmic face of spinal mitochondria to which misfolded SOD1 binds, or misfolded SOD1 conformers unique to spinal cord that have a selective affinity for mitochondrial membranes.

Results

SOD1 Association with Mitochondria Demonstrated by Buoyant Density Centrifugation. By using a single-step enrichment (a continuous iodixanol gradient) to fractionate initial tissue homogenates and in which both protein aggregates and mitochondria will sediment downward after sample loading at the top (19), mutant SOD1 association with mitochondria (especially for the dismutase-inactive mutant hSOD1G85R) has been proposed to represent coenrichment of SOD1 aggregates with mitochondria, rather than mutant association with mitochondria. To enrich for mitochondria while eliminating potential protein aggregates [which are known for all SOD1 mutants (3, 20, 21) but not wild-type (WT) SOD1 (12, 20)], differential sedimentation was initially used to enrich for mitochondria from tissue extracts. After this initial fractionation to remove most soluble components, samples were loaded at the bottom of a density gradient to fractionate initial tissue homogenates and in which both protein aggregates and mitochondria will sediment downward after sample loading at the top (19), mutant SOD1 association with mitochondria (especially for the dismutase-inactive mutant hSOD1G85R) has been proposed to represent coenrichment of SOD1 aggregates with mitochondria, rather than mutant association with mitochondria. To enrich for mitochondria while eliminating potential protein aggregates [which are known for all SOD1 mutants (3, 20, 21) but not wild-type (WT) SOD1 (12, 20)], differential sedimentation was initially used to enrich for mitochondria from tissue extracts. After this initial fractionation to remove most soluble components, samples were loaded at the bottom of a

Author contributions: C.V.V. and D.W.C. designed research; C.V.V. and T.M.M. performed research; N.R.C. contributed new reagents/analytic tools; C.V.V. and D.W.C. analyzed data; and C.V.V. and D.W.C. wrote the paper.

The authors declare no conflict of interest.

1Present address: Department of Medicine, CIUH Research Center, University of Montreal, 1560 Rue Sherbrooke Est, Montreal, QC, Canada H2L 4M1.
2Present address: Department of Neurology, Hope Center for Neurological Disorders, Washington University, School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110.
3To whom correspondence should be addressed. E-mail: dcleveland@ucsd.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0712209105/DC1.

© 2008 by The National Academy of Sciences of the USA
three-step iodixanol gradient and centrifuged. Under these conditions, mitochondria (and any proteins tightly associated with them) migrate upward (float) to their buoyant density (1.13–1.15 g/ml), banding at an interface between the 1.078-g/ml and 1.175-g/ml layers. Soluble or aggregated protein (density 1.26 g/ml), however, sediments downward.

Using multiple transgenic lines, we evaluated whether wild-type or mutant SOD1 protein is present in fractions containing floated mitochondria (Fig. 1A). Varying amounts of endogenous SOD1 and the mitochondrial marker, voltage-dependent anion channel (VDAC) were enriched in floated mitochondria from brain, spinal cord, and liver (Fig. 1 C and D, lanes 3, 6, and 9), in agreement with earlier work (16), and reinforcing the fact that mitochondria from different tissues have variable protein constituents [as most clearly earlier work (16), and reinforcing the fact that mitochondria from cord, and liver (Fig. 1A)] were enriched in floated mitochondria from brain, spinal cord, and liver (Fig. 1A)] were enriched in floated mitochondria from brain, spinal cord, and liver (Fig. 1A)]. The abundant cytosolic marker Hsp90 was largely excluded, as expected. More hSOD1WT coflotated with mitochondria from spinal cord and cortex than those from liver (Fig. 1C, compare lanes 3, 6, and 9). As expected, mitochondrial association of hSOD1WT depended on its cytosolic level, as demonstrated by the comparison of three different hSOD1WT transgenic mouse lines accumulating varying SOD1 levels [supporting information (SI) Fig. 6].

In each of four mutant SOD1 models (hSOD1G93A and hSOD1H46R rats; hSOD1G85R and hSOD1G127X mice), significantly higher levels of each mutant SOD1 were present in floated mitochondria from affected spinal cord tissues compared with liver, a tissue unaffected by disease (Fig. 1 D–F; compare lanes 3, 6, and 9; and SI Fig. 7). Furthermore, comparing spinal cord, brain, and cortical samples from the same animals, a higher proportion of dismutase-inactive mutants hSOD1G85R, hSOD1G127X, and hSOD1H46R floated with spinal cord mitochondria (Fig. 1 E and F, compare lanes 3 and 6; and SI Fig. 7). Almost equivalent levels of the dismutase-active mutant hSOD1G93A floated with mitochondria from both spinal cord and cortex (Fig. 1D, lanes 3 and 6). Low electrophoretic mobility adducts of mutant SOD1 that were detergent- and reducing agent-resistant (reminiscent of oxidized multimers described in ref. 24) also floated with mitochondria, indicating that they are tightly bound to floated mitochondria (Fig. 1 D–F, lanes 3). Thus, human SOD1 is a bona fide resident on or within spinal mitochondria, and there is preferential association of mutant SOD1 with mitochondria within affected tissues.

Dismutase-Inactive SOD1 Is Deposited on the Cytoplasmic-Facing Surface of Spinal Cord, but Not Brain, Mitochondria. Multiple prior efforts have disagreed on how mutant SOD1 is associated with mitochondria. Efforts had argued that association was onto the cytoplasmic-facing mitochondrial surface [for hSOD1G93A (17)], in the intermembrane space (IMS) and the cytoplasmic surface [for hSOD1G93A (17)], in the IMS [for hSOD1G93A (14, 25–27)], and in the matrix [for hSOD1G93A and hSOD1G85R (18)]. To resolve mutant location on floated mitochondria that were free from protein aggregates, protease sensitivity was used to determine the proportion of mutant SOD1 accessible to protease by virtue of location on the cytoplasmic face of intact mitochondria. Because WT SOD1 and WT-like mutants (e.g., hSOD1G93A and hSOD1G127X) are known to be tightly folded, hyperstable proteins that are resistant to proteinase K digestion (28, 29) (Fig. 24), this could only be done for the dismutase-inactive mutants hSOD1H46R, hSOD1G85R, and hSOD1G127X, which are known to be susceptible to protease digestion (28, 29), presumably because of the adoption of less well folded or misfolded conformations. By using a saturating amount of proteinase K (as demonstrated in SI Fig. 8), the majority of each of the three dismutase-inactive mutant SOD1s associated with intact spinal cord mitochondria was protease-sensitive even in
the absence of detergent. Further, the remaining mutant protein (as well as Smac, a protein in the intermembrane space) was completely digested after detergent-mediated solubilization of mitochondrial membranes (Fig. 2A). In cortical mitochondria from the same animals, however, mutant SOD1 proteins remained protease-resistant when membranes were intact. These experiments indicate that these inactive mutant SOD1s are largely deposited onto the cytoplasmic face of the outer mitochondrial membrane but are almost entirely sequestered within brain mitochondria. Additionally, by using anti-peptide antibodies predicted to detect each of the mutants with equal affinity (30), the amount of mutant SOD1 that is sequestered within mitochondria of both tissue types is almost identical.

To assess when mutant protein deposition onto the cytoplasmic surface occurs, we prepared floated mitochondria from asymptomatic hSOD1G85R (6.5 months old) and hSOD1G127X (12 months old) mice, time points at which there are neither clinical signs of disease nor detectable pathology. Most surprisingly, at these early time points, both mitochondrially bound hSOD1G85R and hSOD1G127X in both spinal cord and cortex were almost fully protected from protease K digestion in the absence of detergent (Fig. 2C and D), indicative of location within those mitochondria. Thus, mutant SOD1 deposition on the cytoplasmic face of the outer mitochondrial membrane is not an intrinsic property of SOD1 but is acquired in an age-dependent manner consistent with a pathogenic role in development of age-dependent disease.

Dismutase-Inactive SOD1 Mutants Behave as Integral Membrane Proteins of Spinal Cord, but Not Brain, Mitochondria. Divergent claims have been made concerning whether the association of mutant SOD1 with spinal cord mitochondria is as a loosely membrane-bound or soluble component (18) or is tightly associated with mitochondrial membranes whose linkage is resistant to alkali extraction (17). As an initial test of whether mutant SOD1 binding to the cytoplasmic face of spinal cord mitochondria was mediated by electrostatic interactions, floated mitochondria were repeatedly washed in a high-ionic strength buffer. However, just as was the case for the integral outer membrane protein VDAC, little to no mutant SOD1 was released (Fig. 3), demonstrating a salt-resistant linkage.

Next, although SOD1 protein does not contain any transmembrane segments nor a recognizable mitochondrial targeting signal (which we verified by using the bioinformatics tools DAS-TMfilter, TMPred, TMAP, HMMTOP, SPLICE, PRED-TMR2, and ConPredII), alkali extraction of isolated floated mitochondria from either spinal cord or cortex from a variety of transgenic lines was used to separate peripherally bound membrane components from those more tightly associated (Fig. 4). This revealed that for spinal cord mitochondria, endogenous SOD1 was mostly released, as expected for a soluble component of the intermembrane space (or matrix), or a peripheral membrane component (Fig. 4B, lanes 2, 5, 8, and 11). For mutant SOD1, both alkali-sensitive and alkali-resistant pools were found in spinal cord mitochondria (Fig. 4B, lanes 2 and 3). In contrast, in the alkali-resistant fraction of identically treated cortical mitochondria isolated from the same animal, only a very small proportion of hSOD1G85A was recovered.
Two independent monoclonal antibodies were generated against the DSE2 region (amino acids 125–142). In detergent lysates of floated spinal cord mitochondria, both robustly detected misfolded SOD1 and covalently associated forms that migrated at positions consistent with cross-linked dimeric SOD1 (Fig. 5C, Upper, lanes 2 and 4). No similarly misfolded mutant SOD1 was associated with cortical mitochondria (Fig. 5C, Lower, lanes 2 and 4). Approximately 20% of hSOD1G93A and 50% of hSOD1H46R associated with floated spinal cord mitochondria were in a misfolded conformation that permitted DSE2 antibody binding (Fig. 5D). Protease sensitivity of the usually protease-resistant hSOD1G93A (28, 29) confirmed its misfolded conformation (Fig. 5D, Upper, compare lanes 6 and 8). Neither DSE2 antibody immunoprecipitated any misfolded SOD1 for either SOD1 mutant in the cytosol from either tissue (data not shown). Neither of the antibodies to DSE2 recognized hSOD1WT that had been imported into spinal mitochondria, even after detergent solubilization to liberate internal mitochondrial contents (Fig. 5D).

Recovery of intact, floated mitochondria (in the absence of detergent) by binding to a DSE2 antibody further demonstrated that for both dismutase-active and -inactive mutants, essentially all misfolded SOD1 was bound to spinal cord mitochondria that had antibody-accessible, misfolded SOD1 bound to the cytoplasmic face (Fig. 5E). This misfolded SOD1 was highly selectively enriched onto the outer mitochondrial membrane, with a much smaller proportion (~10%) associated with microsomal fractions (100,000 × g pellet; Fig. 5D, Lower, lanes 6 and 10, and E, Lower, lanes 2 and 6). Thus, mutant hSOD1 is tightly and selectively bound to the cytoplasmic-facing surface of spinal cord mitochondria in a misfolded conformation.

**Discussion**

Floatation of mutant SOD1 protein with spinal cord, but not cortical or liver, mitochondria unambiguously demonstrates that
the presence of these mutant subunits cannot reflect contamination of protein aggregates with mitochondria, as has been proposed (19). Misfolded SOD1 is bound in a very tight, alkali-resistant linkage to the cytoplasmic face of the outer mitochondrial membrane (as shown by protease sensitivity of misfolded, dismutase-inactive mutants). These findings are further supported by immunoelectron microscopy of spinal cord motor neurons in situ in which hSOD1<sup>G93A</sup> is found both within mitochondria and in close proximity to the mitochondrial surface (25). Furthermore, similar studies in hSOD1<sup>GSR</sup> spinal motor neurons also demonstrate a preferential distribution at the mitochondrial surface (C.V.V. and D.W.C., unpublished data). This is common to multiple dismutase-active and -inactive mutants and is found only for mitochondria isolated from tissues at highest risk during disease, findings that support mutant-derived damage to spinal cord mitochondria as a central feature of pathogenesis from ubiquitously expressed SOD1 mutants. Deposition of mutant SOD1 onto the outer membrane may affect protein import, ionic homeostasis, mitochondrial motility, mitochondrial fission/fusion, or regulation of apoptosis. Indeed, an interaction between SOD1 and antiapoptotic Bcl-2 family members, which are residents of the outer mitochondrial membranes, has been proposed (36) but not yet confirmed (37).

A pool of mutant SOD1 is also found within mitochondria, most likely in the intermembrane space, as is known for the WT SOD1 protein. Both the physical properties and the dual localization of SOD1 (cytosol and mitochondria) are reminiscent of those known for yeast adenylate kinase, which is also known to fold rapidly and spontaneously into a thermal- and proteolytic-resistant hyperstable conformation (38). For adenylate kinase, partitioning between cytosol and mitochondria is caused by competition between rapid protein folding and inefficient mitochondrial targeting, i.e., once the protein folds, its cryptic mitochondrial targeting signal is inaccessible. In the context of mutant SOD1, slowed folding kinetics, which has been demonstrated in a cell-free system (39), would result in prolonged exposure of a cryptic targeting sequence.

Use of DSE2 antibodies directed to a normally buried domain of SOD1 has allowed us to determine that misfolded SOD1 conformers are associated with the cytoplasmic face of spinal cord mitochondria but not mitochondria from other tissues. These species have a high affinity for mitochondrial membranes, presupposition through exposure of a normally buried hydrophobic surface (40, 41). Although an inherently misfolded mutant SOD1 would be predicted to bind other intracellular membranes, which would be consistent with previous reports (29, 42), our data clearly demonstrate that misfolded SOD1 conformers are preferentially associated with mitochondria, with only small amounts detectable in microsomal fractions.

Two mechanisms, which are not mutually exclusive, are consistent with age-dependent binding of mutant SOD1 selectively to mitochondrial membranes only on spinal cord mitochondria. First, an enhanced level of a misfolded mutant SOD1 conformer in which a unique surface is exposed [perhaps because of fluctuations of the electrostatic loop (43–45)] may interact with unique, tissue-selective array of cytoplasmic chaperones to facilitate association/presentation to mitochondria. Second, there may be components unique to the cytoplasmic face of spinal mitochondria to which misfolded SOD1 binds. Indeed, it is recognized that mitochondria from different tissues (which perform different biological activities) obligatorily have different protein compositions (22, 23). Furthermore, the tissue type differences reported here call into question the pathological relevance of data collected on mitochondria from tissues that are not the primary target in disease. Combined with the very stable binding (resistance to alkali and high ionic strength), we propose that mutant SOD1 conformers bind to an integral mitochondrial component enriched in spinal mitochondria by exposure of one or more hydrophobic SOD1 surfaces.

In any case, a central determinant for mutant SOD1 association with mitochondria would be the steady-state proportion of misfolded SOD1. Thus, for mutants that adopt a well folded, native-like conformation (like hSOD1<sup>G37R</sup> or hSOD1<sup>G93A</sup>), high total accumulated levels would be required to drive mitochondrial membrane association because only a small proportion of the total protein is accumulated as a misfolded conformer. For dismutase-inactive mutants, accumulation at much lower levels would drive a comparable level of accumulation of misfolded mutant. For both mutant classes, SOD1 harboring ALS-linked mutations have significantly slower folding kinetics in vitro (38). Consistent with all of this, in mice, hSOD1<sup>GSR</sup> causes disease at levels up to 50 times lower than the dismutase-active mutants (3). In human disease as well, the least
stable mutants (accumulating to the lowest levels) correlate with the most rapid disease progression (46).

Finally, mitochondrial association is accompanied by accumulation of low-mobility species, the most prominent of which appears to be a covalently cross-linked dimer. A similar species has recently been shown to be a feature also common in sporadic disease (47), albeit in human disease it remains untested whether this dimer is selective for mitochondria. Determining this is now central to testing whether promiscuous mitochondrial–membrane association of SOD1 may contribute to pathogenesis in sporadic ALS.

Materials and Methods

Mice were deeply anesthetized by isoflurane inhalation and decapitated. Spinal cords were flushed out of the vertebral column with PBS and quickly placed in 5 volumes of ice-cold homogenization buffer (HB) [250 mM sucrose, 10 mM Hepes–NaOH (pH 7.4), 1 mM EDTA plus protease inhibitors). Cortices were quickly dissected from whole brain. Tissues were homogenized with seven strokes of a glass-pestle homogenizer at 4°C and on ice. Homogenates were centrifuged at 1,000g for 15 min to yield S3 and a crude mitochondrial pellet. Crude mitochondria were gently resuspended in HB and then adjusted to 1.204 g/ml Optiprep (iodixanol) and loaded on the bottom of a polycarbonate tube. Mitochondria were overlaid with an equal volume of 1.175 g/ml and 1.078 g/ml Optiprep and centrifuged at 50,000 × g for 4 h (SW-55; Beckman). Mitochondria were collected at the 1.078/1.175 g/ml interface and washed once to remove the Optiprep. Optiprep stock solution (1.32 g/ml, Axis BioShell) was diluted in 250 mM sucrose, 120 mM Hepes–NaOH (pH 7.4), 6 mM EDTA plus protease inhibitors.

Additional materials and methods are discussed in SI Materials and Methods.

ACKNOWLEDGMENTS. We thank Sandrine Da Cruz and Philippe Parone for valuable discussions and Gregory Cox (Jackson Laboratory, Bar Harbor, ME), Mikael Johnsson (Umeå University, Umeå, Sweden), Stefan Marklund (Umeå University, Umeå, Sweden), Pak Chan (Stanford University, Palo Alto, CA), and Masashi Aoki (Tohoku University, Sendai, Japan) for generously sharing transgenic animals. This work was supported by National Institutes of Health Grant NS 27036 (to D.W.C.) C.V. is supported by a Developmental Grant from the Muscular Dystrophy Association. D.W.C. is supported by the Ludwig Institute for Cancer Research.